Clinical Study
Effects of Flash Glucose Monitoring on Dietary Variety, Physical Activity, and Self-Care Behaviors in Patients with Diabetes
Table 1
Characteristics of the diabetic study group.
| | Variables | Mean (SD) or % | Variables | Mean (SD) or % |
| | Age (years) | 57.3 (15.7) | Retinopathy, % | 45.1 | | Women, % | 52.0 | Neuropathy, % | 62.1 | | Body weight (kg) | 64.1 (15.3) | Nephropathy, % | 44.7 | | BMI (kg/m2) | 24.3 (5.4) | CVD, % | 14.2 | | T1DM/T2DM (numbers) | 42/48 | Medication | | | HbA1c (%) | 7.7 (1.2) | α-Glucosidase inhibitors, % | 8.3 | | Duration of diabetes (years) | 18.4 (11.2) | DPP4 inhibitors, % | 37.5 | | Alcohol consumption, % | 22.7 | Sulfonylureas, % | 16.6 | | Smoking, % | 21.2 | Biguanides, % | 64.5 | | Hypertension, % | 41.8 | Glinides, % | 4.1 | | Dyslipidemia, % | 50.5 | SGLT2 inhibitors, % | 37.5 | | LDLC (mg/dL) | 102.9 (27.7) | Pioglitazone, % | 18.7 | | HDLC (mg/dL) | 58.1 (18.5) | GLP-1 analog, % | 15.5 | | TG (mg/dL) | 144.2 (81) | Insulin, % | 100 |
|
|
SD: standard deviation; BMI: body mass index; T1DM/T2DM: type 1 diabetes mellitus/type 2 diabetes mellitus; HbA1c: hemoglobin A1c; LDLC: low-density lipoprotein cholesterol; HDLC: high-density lipoprotein cholesterol; TG: triglyceride; GLP-1: glucagon-like peptide-1; DPP4: dipeptidyl peptidase 4; SGLT2: sodium-glucose cotransporter 2; CVD: cardiovascular diseases.
|
